Sinopsis
PeerView is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Episodios
-
![Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment]()
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
11/10/2021 Duración: 51minGo online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, and other team members can collaborate to overcome the many challenges of VOD/SOS. Upon completion of this activity, participants should be better able to: Explain the clinical signs, symptoms, and medical burden of VOD/SOS to patients preparing for transplantation, Apply team-based approaches to risk assessment and diagnostic confirmation of VOD/SOS, including interpretation of clinical symptoms/disease onset and use of techniques such as ultrasound imaging or other strategies as appropriate, Use modern adverse event severi
-
![Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy]()
Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
15/09/2021 Duración: 59minGo online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an
